| Title |
Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma
|
|---|---|
| Published in |
Drug Design, Development and Therapy, March 2017
|
| DOI | 10.2147/dddt.s98053 |
| Pubmed ID | |
| Authors |
Reed Friend, Manisha Bhutani, Peter Voorhees, Saad Usmani |
| Abstract |
Elotuzumab is one of the first monoclonal antibodies to be approved for the treatment of multiple myeloma. It is a humanized immunoglobulin G kappa (IgGκ) antibody that targets signaling lymphocytic activation molecule family member 7 (SLAMF7), a surface marker that is highly expressed on normal and malignant plasma cells. This review summarizes the preclinical and clinical data that led to the approval of elotuzumab, along with a discussion on the ongoing and future clinical investigations. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 31 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 8 | 26% |
| Other | 7 | 23% |
| Researcher | 3 | 10% |
| Professor | 3 | 10% |
| Student > Master | 2 | 6% |
| Other | 2 | 6% |
| Unknown | 6 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 29% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 10% |
| Agricultural and Biological Sciences | 2 | 6% |
| Immunology and Microbiology | 2 | 6% |
| Biochemistry, Genetics and Molecular Biology | 2 | 6% |
| Other | 4 | 13% |
| Unknown | 9 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 June 2020.
All research outputs
#7,277,460
of 22,962,258 outputs
Outputs from Drug Design, Development and Therapy
#496
of 2,097 outputs
Outputs of similar age
#117,809
of 311,254 outputs
Outputs of similar age from Drug Design, Development and Therapy
#15
of 51 outputs
Altmetric has tracked 22,962,258 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 2,097 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 311,254 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 61% of its contemporaries.
We're also able to compare this research output to 51 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.